Isolation and characterization of an estrogen binding protein which may integrate the plethora of estrogenic actions in nonreproductive organs

Journal of Steroid Biochemistry and Molecular Biology

Volumn 65, Issue 1-6, 1998, Pages 3-41

  Rao, Bantwal Ramanath ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; BIOFLAVONOID; CARCINOGEN; ESTRADIOL; ESTRIOL; ESTROGEN; ESTROGEN BINDING PROTEIN; ESTRONE; PROTEIN SUBUNIT; SERINE PROTEINASE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; BREAST CARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROTEIN ISOLATION; PROTEIN LOCALIZATION; PROTEIN STABILITY; RAT;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTIBODY SPECIFICITY; ANTIPSYCHOTIC AGENTS; BINDING, COMPETITIVE; CALMODULIN; CHICKENS; ESTRADIOL; ESTRIOL; ESTROGENS; ESTRONE; FEMALE; GENITALIA, FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; MALE; MICE; PHOSPHORIC MONOESTER HYDROLASES; PROSTATE; RATS; RECEPTORS, ESTROGEN; SULFHYDRYL REAGENTS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0032052830     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(98)00019-3     Document Type: Conference Paper

References (156)

1. Walters M. R. Steroid hormone receptors and the nucleus. Endocr. Rev. 6:1985;512-543.
2. Truss M., Beato M. Steroid hormone receptors: Interaction with deoxyribonucleic acid and transcription factors. Endocr. Rev. 14:1993;459-479.
3. Ciocca D. R., Vargas Roig L. M. Estrogen receptors in human nontarget tissues: Biological and clinical implications. Endocr. Rev. 16:1995;35-62.
4. White M. M., Zamudio S., Stevens T., Tyler R., Lindenfeld J., Leslie K., Moore L. G. Estrogen, progesterone, and vascular reactivity: Potential cellular mechanisms. Endocr. Rev. 16:1995;739-751.
5. Jensen E. V., Suzuki T., Kawashima T., Stumpf W. E., Jungblut P. W., DeSombre E. R. A two step mechanism for the interaction of estradiol with rat uterus. Proc. Natl. Acad. Sci. U.S.A. 59:1968;632-638.
6. Jensen E. V. Intracellular localization of estrogen receptors: implications for interaction mechanism. Lab. Invest. 51:1984;487-492.
7. Jensen E. V. Editorial: Some newer endocrine aspects of breast cancer. New Engl. J. Med. 291:1974;1252-1254.
8. Jensen E. V., DeSombre E. R. Estrogen-receptor interaction [Review]. Science. 182:1973;126-134.
9. Jensen E. V., DeSombre E. R. Mechanism of action of the female sex steroids. Annu. Rev. Biochem. 41:1972;203-230.
10. O'Malley B. W., Means A. R. Female steroid hormones and target cell nuclei. Science. 183:1974;610-620.
11. Annunziato L., Moore K. E. Prolactin in CSF selectively increases dopamine turnover in the median eminence. Life Sci. 22:1978;2037-2042.
12. Eikenburg D. C., Ravitz A. J., Gudesky G. A., Moore K. E. Effects of estrogens on prolactin and tuberoinfundibular dopamine neurons. J. Neural. Transm. 40:1978;235-244.
13. Labrie, F., Beulieu, M., Caron, M. and Raymond, V. (1978) The adeno-hypophyseal dopamine receptors, specificity and modulation of its activity by estradiol. In Proceedings of Intl. Symp. on Prolactin, ed. C. Robin and M. Harter, pp. 121-136. Elsvier/North Holland, Amsterdam.
14. Lieberman M. E., Maurer R. A., Gorski J. Estrogen control of prolactin synthesis in vitro. Proc. Natl. Acad. Sci. U.S.A. 75:1978;5946-5949.
15. Nicoll C. S., Meiters J. Prolactin secretion in vitro. Effects of gonadal and adrenal cortical steroids. Proc. Soc. Exp. Biol. Med. 117:1964;579-583.
16. Raymond V., Beulieu M., Labrie F., Boissier J. R. Potent anti-dopaminergic activity of estradiol at the rat pituitary level on prolactin release. Science. 200:1978;1173-1175.
17. Bedard P., Dankova J., Boucher R., Langelier P. Effect of estrogens on apomorphine-induced circling behavior in the rat. Can. J. Physiol. Pharmacol. 56:1978;538-541.
18. Bedard, P., Langelier, P., Dankova, J., Villeeeuve, A., Di Paolo, T., Barden, N., Labrie, F., Boissier, J. R. and Euvrard, C. (1979) Estrogens, progesterone and the extrapyramidal system. In Extra-Pyramidal System and its Disorders. Advances in Neurology Series, ed. W. Poirier, T. L. Sourkes and P. Bedard, pp. 411-422. Raven press, New York.
19. Bedard P., Langelier P., Villeneuve A. Estrogens and extrapyramidal system. Lancet. 2:1977;1367-1368.
20. Euvrard C., Labrie F., Boissier J. R. Effect of estrogen on changes in the activity of striatal cholinergic neurons induced by DA drugs. Brain Res. 169:1979;215-220.
21. Becker R. C. Coronary artery disease in women: risks and prevention. Coronary Acute Care. 3:1992;2-10.
22. Bush T. L. The epidemiology of cardiovascular disease in postmenopausal women. Ann. N.Y. Acad. Sci. 592:1990;263-271.
23. Henderson B. E., Ross R. K., Paganini-Hill A., Mack T. M. Estrogen use and cardiovascular disease. Am. J. Obstet. Gynecol. 154:1986;1181-1186.
24. Stampfer M. J., Colditz G. A., Willett W. C., Manson J. E., Rosner B., Speizer F. E., Hennekens C. H. Postmenopausal estrogen therapy and cardiovascular disease. Ten year follow-up from the nurses, health study. New Eng. J. Med. 325:1991;756-762.
25. Horowitz M. C. Cytokines and estrogen in bone. Antiosteoporotic effects. Science. 260:1993;626-627.
26. Girasole G., Jilka R. L., Passeri G., Boswell S., Boder G., Williams D. C., Manolagas S. C. 17β-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro. J. Clin. Invest. 89:1992;883-891.
27. Pacifico R., Brown C., Puscheck E., Friedrich E., Slatopolsky E., Maggio D., McCracken R., Avioli L. V. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc. Natl. Acad. Sci. U.S.A. 88:1991;5134-5137.
28. Pacifico R., Rifas L., McCracken R., Vered I., McMurtry C., Avioli L. V., Peck W. A. Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release. Proc. Natl. Acad. Sci. U.S.A. 86:1989;2398-2402.
29. Chaudhary L. A., Spelsberg T. C., Riggs B. L. Production of various cytokines by normal human osteoblast-like cells in response to interleukin-1β and tumor necrosis factor-α: Lack of regulation by 17β-estradiol. Endocrinology. 130:1992;2528-2533.
30. Grodstein F., Stampfer M. J., Manson J. E., Colditz G. A., Willett W. C., Rosner B., Speizer F. E., Hennekens C. H. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. New Engl. J. Med. 335:1996;453-461.
31. Tang M. X., Jacobs D., Stern Y., Marder K., Schofield P., Andrews H., Mayeux R. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 348:1996;429-432.
32. McGuire W. L. Steroid hormone receptors in breast cancer treatment strategy. Rec. Prog. Horm. Res. 38:1980;135-156.
33. Hierowski M., Madon J. Influence of 20-methylcholanthrene on 17β-estradiol binding to 9.5S receptor molecule from rat uterus. Biochem. Biophys. Acta. 170:1968;425-427.
34. Heizmann C. W., Wyss H. I. Comparison of the binding of 7,12-dimethylbenzanthracene and estradiol 17β in the calf uterus cytosol. Steroids. 20:1972;499-514.
35. Brecher P. I., Wotiz H. H. Stereospecificity of the uterine nuclear hormone receptors. Proc. Soc. Exp. Biol. Med. 128:1968;470-473.
36. Toft D., Spelsberg T. C. A distinction between 3 methylcholanthrene and estrogen binding in the uterus. Cancer Res. 32:1972;2743-2749.
37. Keightley D. D., Okey A. B. Effects of dime thylbenzanthracene and dihydrotestosterone on estradiol-17β binding in rat mammary cytosol fraction. Cancer Res. 33:1973;2637-2642.
38. Schneider S. L., Vitants A., Morreal C. E., Sinha D. K., Dao T. L. Estrogenic properties of 3,9-dimethylbenzanthracene, a potential metabolite of benzanthracene. J. Natl. Cancer Inst. 57:1976;1351-1354.
39. Colborn, T., Dumanoski, D. and Myers, J. P. (1966) Our Stolen future. Are We Threatening Our Fertility, Intelligence, and Survival? - A Scientific Detective Story. A Dutton Book, New York.
40. Rao, B. R. (1995) Estrogen Receptors are not Involved in Estrogenic Action of Bisdehydrodoisynolic Acid. Recent Progress in Hormone Research. Portland, U.S.A.
41. Meyers C. Y., Kolb V. M., Gass G. H., Rao B. R., Roos C. F., Dandliker W. B. Doisynolic-type acids-uterotopically potent estrogens which compete poorly with estradiol for cytosolic estradiol receptors. J. steroid Biochem. 31:1988;393-404.
42. Power R. F., Lydon J. P., Conneely O. M., O'Malley B. W. Dopamine activation of an orphan of the steroid receptor superfamily. Science. 252:1991;1546-1548.
43. Wehling, M. (ed) (1995) The Genomic and Non-Genomic Effects of Aldosterone. CRC Press, Bucca Raton.
44. Fisher D. K., Higgins T. J. A sensitive high-volume, colorimetric assay for protein phosphatase. Pharmac. Res. 11:1994;759-763.
45. DeSombre E. R., Lyttle C. R. Isolation and purification of rat mammary tumor peroxidase. Cancer Res. 57:1976;1093-1097.
46. Jensen E. V., Greene G. L., Closs L. E., DeSombre E. R., Nadji M. Receptors reconsidered: A 20-year perspective. Rec. Prog. Horm. Res. 38:1982;1-40.
47. Clark J. H., Markaverich B. M., Upchurch S., Eriksson H., Hardin J. W., Peck E. J. Jr. Heterogeneity of estrogen binding sites: Relationship to estrogen receptors and estrogen responses. Rec. Prog. Horm. Res. 36:1980;89-134.
48. Markaverich B. M., Roberts R. R., Alejandro M. A., Johnson G. A., Middleditch B. S., Clark J. H. Bioflavonoid interaction with rat uterine type II binding sites and cell growth inhibition. J. Steroid Biochem. 30:1988;71-78.
49. Markaverich B. M., Gregory R. R. Preliminary characterization and partial purification of rat uterine nuclear type II binding sites. Biochem. Biophys. Commun. 177:1991;1283-1290.
50. Horigome T., Golding T. S., Quarmby V. E., Lubahn D. B., McCarty K. Sr., Korach K. S. Purification and characterization of mouse uterine estrogen receptor under conditions varying hormonal status. Endocrinology. 121:1987;2099-2111.
51. Szego C. M. The lysosome as a mediator of hormone action [Review]. Rec. Prog. Horm. Res. 30:1974;171-233.
52. Szego C. M., Pietras R. J. Subcellular distribution of oestrogen receptors [letter]. Nature. 317:1985;88-89.
53. Pietras R. J., Szego C. M. Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature. 265:1977;69-72.
54. Pietras R. J., Szego C. M. Partial purification and characterization of oestrogen receptors in subfractions of hepatocyte plasma membranes. Biochem. J. 191:1980;743-760.
55. Pietras R. J., Szego C. M. Metabolic and proliferative responses to estrogen by hepatocytes selected for plasma membrane binding-sites specific for estradiol-17beta [Review]. J. Cell. Physiol. 98:1979;145-159.
56. Pink J. J., Jiang S.-J., Fritsch M., Jordan V. C. An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen-related protein. Cancer Res. 55:1995;2583-2590.
57. Watson C. S., Pappas T. C., Gametchu B. The other estrogen receptor in the plasma membrane: Implications for the actions of environmental estrogens. Environ. Health Perspect. 103:1995;42-50.
58. Giguère V., Yang N., Segui P., Evans R. M. Identification of a new class of steroid hormone receptors. Nature. 331:1988;91-94.
59. Kuiper G. G. J. M., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J. A. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U.S.A. 93:1996;5925-5930.
60. Fox, H. S. (1995) Sex steroids and immune system. In Non-Reproductive Actions of Sex Steroids, pp. 203-217. Wiley, Chichester (Ciba foundation symposium 191).
61. Olsen N. J., Kovacs W. J. Gonadal steroids and immunity. Endocr. Rev. 17:1996;369-384.
62. Paavonen T. Hormonal regulation of immune response. Trends in molecular medicine. Ann. Med. 26:1994;255-258.
63. Kincade P. W., Medina K. L., Smithson G. Sex hormones as regulators of lymphopoiesis. Immunol. Rev. 137:1994;119-134.
64. Schuurs A. H., Verheul H. A. Effects of gender and sex steroids on the immune system. J. steroid Biochem. 25:1990;157-172.
65. Sthoeger Z. M., Chiorazzi N., Lahita R. G. Regulation of the immune response by sex hormones. I. In vitro effects of estradiol and testosterone on pokeweed mitogen-induced human B cell differentiation. J. Immunol. 141:1988;91-98.
66. Seaman W. E., Gindhart T. D. Effect of estrogen on natural killer cells. Arthritis Rheumatism. 22:1979;1234-1240.
67. Fearson D. T., Locksley R. M. The instructive role of innate immunity in the acquired immune response. Science. 272:1996;50-54.
68. Schriber S. L., Crabtree G. R. The mechanism of action of cyclosporin A and FK506. Immunol. Today. 13:1992;136-142.
69. Rosborough S. L., Fleming M., Nelson P. A., Boger J., Harding M. W. Identification of FKBP-related proteins with antibodies of predetermined specificity and isolation by FK506 affinity chromatography. Transplant. Proc. 23:1991;2890-2893.
70. Meyers B. D., Ross J., Newton L., Luetscher J., Perloth M. Cyclosporine-associated chronic nephropathy. New Engl. J. Med. 311:1984;699-705.
71. Feutern G., Mihatsch M. J. For the International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. New Engl. J. Med. 326:1992;1654-1660.
72. Fathman C. G., Myers B. D. Cyclosporine therapy for autoimmune disease. New Engl. J. Med. 326:1992;1693-1694.
73. Sharkey J., Butcher S. P. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. Nature. 371:1994;336-339.
74. Byar D. P. The veterans Administration Cooperative Urological Research Group's studies of the prostate. Cancer. 32:1973;1126-1130.
75. Brautigan D. L. Great expectations: Protein tyrosine phosphatases in cell regulation. Biochim. Biophys. Acta. 1114:1992;63-77.
76. Walton K. M., Dixon J. E. Protein tyrosine phosphatases. Annu. Rev. Biochem. 62:1993;101-120.
77. p21. Proc. Natl. Acad. Sci. U.S.A. 88:1991;5036-5040.
78. Cohen P. The structure and regulation of protein phosphatases. Annu. Rev. Biochem. 58:1989;453-508.
79. Klee C. B., Krinks M. H., Manalan A. S., Cohen P., Stewart P. Isolation and characterization of bovine brain calcineurin: A calmodulin-stimulated protein phosphatase. Methods Enzymol. 102:1983;227-244.
80. Auricchio F., Migliaccio, Casoria G., Rotondi A., Di Domenico M., Chambon P., Auricchio F. Calmodulin-stimulated estradiol receptor-tyrosine kinase. Methods Enzymol. 139:1987;731-744.
81. Castoria G., Migliaccio A., Green S., Di Domenico M., Chambon P., Auricchio F. Properties of a purified estradiol-dependent calf uterus tyrosine kinase. Biochemistry. 32:1993;1740-1750.
82. Arnold S. F., Obourn J. D., Jaffe H., Notides A. C. Phosphorylation of the human estrogen receptor on tyrosine 537 in vivo and by Src family tyrosine kinases in vitro. Mol. Endocrinol. 9:1995;24-33.
83. Bouhoute A., Leclercq G. Antagonistic effect of triphenylethylenic antiestrogens of the association of estrogen to calmodulin. Biochem. Biophys. Res. Commun. 184:1992;1432-1440.
84. Bliska J. B., Guan K. L., Dixon J. E., Falkow S. Tyrosine phosphate hydrolysis of host proteins by an essential Yersinia virulence determinant. Proc. Natl. Acad. Sci. U.S.A. 88:1991;1187-1191.
85. Pallen C. J., Lai D. S., Chia H. P., Boulet I., Tong P. H. Purification and characterization of a higher-molecular-mass form of protein phosphotyrosine phosphatase (PTP 1B) from placental membranes. Biochem. J. 276:1991;315-323.
86. Dillmann, R. (1990) Alzheimer's disease. The concept of disease and the construction of medical knowledge. Thesis, Vrije Universiteit, Amsterdam.
87. Burns, A., Howard, R. and Pettit T. (1995) Alzheimer's Disease: A Medical Companion. Blackwell Science, pp. 25-153.
88. Chiodo L. A., Caggiula A. R. Alterations in basal firing rate and autoreceptor sensitivity of dopamine neurons in the substantia nigra following acute and extended exposure to estrogen. Eur. J. Pharmcol. 67:1980;165-166.
89. Tang M. X., Jacobs D., Stern Y., Marder K., Schofield P., Andrews H., Mayeux R. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 348:1996;429-432.
90. Lee V. M. Y., Balin B. J., Otvos L. Jr., Trojanowski J. Q. A68: A major subunit of paired helical filaments and derived forms of normal Tau. Science. 251:1991;675-678.
91. Paudel H. K., Lew J., Ali Z., Wang J. H. Brain proline-directed protein kinase phosphorylates Tau on sites that are abnormally phosphorylated in Tau associated with Alzheimer's paired helical filaments. J. Biol. Chem. 268:1993;23512-23518.
92. Vulliet R., Halloran S. M., Braun R. K., Smith A. J., Lee G. Proline-directed phosphorylation of human Tau protein. J. Biol. Chem. 267:1992;22570-22574.
93. Arendt T., Hanisch F., Holzer M., Brückner In vivo phosphorylation in the rat basal nucleus induces PHF-like and APP immunoreactivity. NeuroReport. 5:1994;1397-1400.
94. Arendt, T., Holzer, M., Fruth, R., Brückner, M. K. and Gärtner, U., Paired helical filament-like phosphorylation of Tau, deposition of β/A4-amyloid and memory impairment in rat induced by chronic inhibition of phosphatase 1 and 2A. Neuroscience (personal communication).
95. Arendt, T., Fruth, R., Holzer, M. and Brückner, M. K. (1995) Induction of Alzheimer-type pathology in rat brain by chronic stimulation of protein phosphorylation. In The meeting of European Neuroscience, Amsterdam, The Netherlands, 3-7 sept. Abstract # 12.03.
96. Lesort, M., Couratier, P., Esclaire, F., Yardin, C. and Hugon, J. (1995) Protein kinase C activation induces neuronal Tau phosphorylation at serine 202. In The meeting of European Neuroscience, Amsterdam, The Netherlands, 3-7 sept. Abstract # 50.37.
97. Singh T. J., Zaidi T., Grundke-Iqbal I., Iqbal K. Non-proline-dependent protein kinases phosphorylate several sites found in tau from Alzheimer disease brain. Mol. Cell. Biochem. 154:1996;143-151.
98. Alonso A. D. C., Grundke-Iqbal I., Barra H. S., Iqbal K. Abnormal phosphorylation of tau and the mechanism of Alzheimer's neurofibrillary degeneration: Sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc. Natl. Acad. Sci. U.S.A. 94:1997;298-303.
99. Gong C. X., Shaikh S., Wang J. Z., Zaidi T., Grundke-Iqbal I., Iqbal K. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J. Neurochem. 65:1995;732-738.
100. Wang J. Z., Gong C. X., Zaidi T., Grundke-Iqbal I., Iqbal K. Dephosphorylation of Alzheimer paired helical filaments by protein phosphatase-2A and -2B. J. Biol. Chem. 270:1995;4854-4860.
101. Wehling, M. (ed) (1995) The Genomic and Non-Genomic Effects of Aldosterone. CRC Press, Bucca Raton.
102. Lieberherr M., Gross B. Androgens increase intracellular calcium concentration and inositol 1,4,5-triphosphate and diacylglycerol formation via a pertussis toxin-sensitive G-protein. J. Biol. Chem. 269:1994;7217-7223.
103. Szego C. M., Pietras R. J. Lysosomal functions in cellular activation: propagation of the actions of hormones and other effectors. Int. Rev. Cytol. 88:1984;1-302.
104. 2+ influx and the acrosome reaction in human sperm. Cell Signal. 5:1993;531-538.
105. Koening H., Fan C. C., Goldstone A. D., Lu C. Y., Trout J. J. Polyamines mediate androgenic stimulation of calcium fluxes and membrane transport in rat heart myocytes. Circ. Res. 64:1989;415-426.
106. Bression D., Michard M., LeDafniet M., Pagesy P., Peillon F. Evidence for specific estradiol binding site on rat pituitary membranes. Endocrinology. 119:1986;1048-1051.
107. Villeneuve A., Langlier P., Bédard P. Estrogens, dopamine and dyskinesias. Can. Psychiatr. Assoc. J. 23:1978;68-70.
108. Euvrard C., Oberlander C., Boissier J. R. Antidopaminergic effect of estrogens at the striated level. J. Pharmacol. Exp. Ther. 214:1980;179-185.
109. Chiodo L. A., Caggiula A. R. Alterations in basal firing rate and autoreceptor sensitivity of dopamine neurons in the substantia nigra following acute and extended exposure to estrogen. Eur. J. Pharmacol. 67:1980;165-166.
110. Klaiber E. L., Broverman D. M., Vogel W., Kobayashi Y. Estrogen therapy for severe persistent depressions in women. Arc. Gen. Psychiatry. 36:1979;550-554.
111. Gamboa E. T., Isaacs G., Harter D. H. Chorea associated with oral contraceptive therapy. Arch. Neurol. 25:1971;112-114.
112. Villeneuve A., Cazejust T., Côté M. Estrogens in tardive dyskinesia in male psychiatric patients. Neuropsychobiol. 6:1980;145-151.
113. Coppen A., Kessel N. Menstruation and personality. Br. J. Psychiat. 109:1963;711-721.
114. Gordon J. H. Modulation of apomorphine-induced stereotypy by estrogen: Time course and dose response. Brain Res. Bull. 5:1980;679-682.
115. Gordon J. H., Gorski R. A., Borison R. L., Diamond B. I. Postsynaptic efficacy of dopamine: Possible suppression by estrogen. Pharmacol. Biochem. Behav. 12:1980;515-518.
116. Chiodo L. A., Caggiula A. R., Saller C. F. Estrogen potentiates the stereotypy induced by dopamine agonists in the rat. Life Sci. 28:1981;827-835.
117. Arnauld E., Dufy B., Pestre M., Vincent J. D. Effects of estrogens on the responses of caudate neurons to micro-iontophoretically applied dopamine. Neurosci. Lett. 21:1981;325-331.
118. Eriksen E. F., Colvard D. S., Berg N. G., Graham M. L., Mann K. G., Spelsberg T. C., Riggs B. L. Evidence of estrogen receptors in normal human osteoblast-like cells. Science. 241:1988;84-86.
119. Komm B. S., Terpening C. M., Benz D. J., Graeme K. A., Gallegos K. A., Korc M., Greene G. L., O'Malley B. W., Haussler M. R. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science. 241:1988;81-84.
120. Slootweg M. C., Ederveen A. G. H., Schot L. P. C., Schoonen W. G. E. J., Kloosterboer H. J. Oestrogen and progesterone synergistically stimulate human and rat osteoblast proliferation. J. Endocrinol. 133:1992;R5-R8.
121. Turner R. T., Riggs B. L., Spelsberg T. C. Skeletal effects of estrogen. Endocr. Rev. 15:1994;275-300.
122. Riggs, B. L. and Spelsberg, T. C. (1996) Mechanism of estrogen action on bone cells. In Osteoporosis, ed. S. E. Papapoulos, P. Lips, H. A. P. Pols, C. C. Johnston and P. D. Delmas, pp. 241-250. Elsevier, Amsterdam.
123. Pols, H. A. P. and Burckhardt, P. (1996) Estrogens and estrogen agonists/antagonists. In Osteoporosis, ed. S. E. Papapoulos, P. Lips, H. A. P. Pols, C. C. Johnston and P. D. Delmas, pp. 239-240. Elsevier, Amsterdam.
124. Girasole G., Jilka R. L., Passeri G., Boswell S., Boder G., Williams D. C., Manolagas S. C. 17β-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J. Clin. Invest. 89:1992;883-891.
125. Kassem M., Harris S. A., Spelsberg T. C., Riggs B. L. Estrogen inhibits interleukin-6 production and gene expression in a human osteoblastic cell line with high levels of estrogen receptors. J. Bone Min. Res. 11:1996;193-199.
126. Hogasen A. K. M., Nordsletten L., Aasen A. O., Falch J. A. There is no difference in spontaneous and 17β-estradiolinduced interleukin-1β release by peripheral blood mononuclear cells from nonosteoporotic women with different rates of early postmenopausal bone loss. J. Clin. Endocrinol. Metab. 80:1995;2480-2484.
127. Walsh P. C., Wilson J. D. Induction of prostatic hyperplasia in the dog with androstandiol. J. Clin. Invest. 57:1976;1093-1097.
128. deKlerk D. P., Coffey D. S., Ewing L. L., McDermott I. R., Reiner W. G., Robinson C. H., Scott W. W., Strandberg J. D., Talalay P., Walsh P. C., Wheaton L. G., Zirkin B. R. A comparison of spontaneous and experimentally induced canine prostatic hyperplasia. J. Clin. Invest. 64:1979;842-849.
129. Massas R., Servadio C., Sandbank U., Abramovici A. Immunocytochemistry of epithelial markers in citral-induced prostate hyperplasia in rats. Histol. Histopathol. 6:1991;183-189.
130. Sandbank M., Abramovici A., Wolf R., Ben David E. Sebaceous gland hyperplasia following topical application of citral. An ultrastructural study. Am. J. Dermatopathol. 10:1988;415-418.
131. Abramovici A., Servadio C., Shmuely J., Sandbank U. Experimental induction of atypical hyperplasia in rat ventral prostate. Prog. Clin. Biol. Res. 243A:1987;559-568.
132. Servadio C., Abramovici A., Sandbank U., Savion M., Rosen M. Early stages of the pathogenesis of rat ventral prostate hyperplasia induced by citral. Eur. Urol. 12:1986;195-200.
133. Geldof A. A., Engel C., Rao B. R. Estrogenic action of commonly used fragrant agent citral induces prostatic hyperplasia. Urol. Res. 20:1992;139-144.
134. Abramovici A., Sandbank U. The mortician's mystery solved? [letter]. New Engl. J. Med. 319:1988;1157.
135. Arai A., von Hintzenstern J., Kiesewtter F., Schell H., Hornstein O. P. In vitro effects of testosterone, dihydrotestosterone and estradiol on cell growth of human hair bulb papilla cells and hair root sheath fibroblasts. Acta Dermato-Venereologica. 70:1990;338-341.
136. Kiesewetter F., Arai A., von Hintzenstern J., Schell H. Effects of testosterone, dihydrotestosterone and estradiol on growth of human hair outer root sheath keratinocytes in vitro. Arch. Dermatol. Res. 283:1991;476-479.
137. Vaillant L., Callens A. Skin and esthetic alterations in menopause. Rep. Humaine Horm. 8:1995;203-208.
138. Hardy M. H. The secret life of the hair follicle [Review]. Trends Genet. 8:1992;55-61.
139. Cotsarelis G., Sun T. T., Lavker R. M. Label-retaining cells reside in the bulge area of pilosebaceous unit: implications for follicular stem cells, hair cycle, and skin carcinogenesis. Cell. 61:1990;1329-1337.
140. Morris R. J., Fischer S. M., Slaga T. J. Evidence that the centrally and peripherally located cells in the murine epidermal proliferative unit are two distinct cell populations. J. Invest. Dermatol. 84:1985;277-281.
141. Oh H.-S., Smart R. An estrogen receptor pathway regulates the telogen-anagen hair follicle transition and influences epidermal cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 93:1996;12525-12530.
142. Hozumi Y., Imaizumi T., Kondo S. Effect of cyclosporin on hair-existing area of nude mice. J. Dermatol. Sci. 7:1994;33-38.
143. Bisaria K. K. Effect of estrogen on lens epithelium in the albino rat. Indian J. Physiol. Pharmacol. 24:1980;357-360.
144. Guivernau M., Terragno A., Dunn M. W., Terragno N. A. Estrogens induce lipoxygenase derivative formation in rabbit lens. Invest. Opthalmol. Visual Sci. 23:1982;214-217.
145. Klein B. E., Klein R., Ritter L. L. Is there evidence of an estrogen effect on age-related lens opacities? The Beaver Dam Eye Study. Arch. Opthalmol. 112:1994;85-91.
146. Colborn T., vom Saal F. S., Soto A. M. Developmental effects of endocrine-disrupting chemicals in wildlife and humans [see comments] [Review]. Environ. Health Perspec. 101:1993;378-384.
147. Van Kesteren, P. J. M. (1996) Clinical and metabolic aspects of cross-sex hormone treatment in transexuals. Thesis, Vrije Universiteit. Copyprint, Enschede, The Netherlands.
148. Herbst A. L., Anderson D. Clear cell adenocarcinoma of the vagina and cervix secondary to intrauterine exposure to diethylstilbestrol [Review]. Sem. Surg. Oncol. 6:1990;343-346.
149. Sharp G. B., Cole P., Anderson D., Herbst A. L. Clear cell adenocarcinoma of the lower genital tract. Correlation of mother's recall of diethylstilbestrol history with obstetrical records. Cancer. 66:1990;2215-2220.
150. Herbst A. L. The effects in the human of diethylstilbestrol (DES) use during pregnancy. Princess Takamatsu Symposia. 18:1987;67-75.
151. Kuiper G. G., Gustafsson J. A. The novel estrogen receptor-beta subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens [Review]. FEBS Lett. 410:1997;87-90.
152. Byers M., Kuiper G. G., Gustafsson J. A., Park-Sarge O. K. Estrogen receptor beta mRNA expression in rat ovary: down-regulation by gonadotropins. Mol. Endocrinol. 11:1997;72-82.
153. Gustafsson J. A. Estrogen receptor beta-getting in on the action? [news]. Nature Med. 3:1997;493-494.
154. Kuiper G. G., Carlsson B., Grandien K., Enmark E., Haggblad J., Nilsson S., Gustafsson J. A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 138:1997;863-870.
155. Kuiper G. G., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J. A. Cloning of a novel receptor expressed in rat prostate and ovary. PNAS, U.S.A. 93:1996;5925-5930.
156. Katzenellenbogen B. S., Korach K. S. Editorial: A new actor in the estrogen receptor drama-Enter ER-β Endocrinology. 138:1997;861-862.